Metrikler
Yayın
156
Açık Erişim
41
BM Sürdürülebilir Kalkınma Amaçları
Makaleler
Tümü (145)
SCI-E, SSCI, AHCI (127)
SCI-E, SSCI, AHCI, ESCI (137)
ESCI (8)
Scopus (134)
TRDizin (15)
Diğer Yayınlar (1)
2025
20251. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer
YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.
Acta Medica
, cilt.56, sa.3, ss.186-198, 2025 (TRDizin)
2025
20252. Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi
kahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.
Turkish Journal of Clinics and Laboratory
, cilt.16, sa.2, ss.255-262, 2025 (TRDizin)
2025
20253. Early Changes in Volumetric Body Composition Parameters Predict Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy
AKTEPE O. H., ERDEMİR A. G., Yildirim E. C., Demirciler E., ULAŞLI T., GÜVEN D. C., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.9, 2025 (SCI-Expanded, Scopus)
2025
20254. Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors
ŞAHİN T. K., AKSOY S., GÜVEN D. C.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.5, ss.471-484, 2025 (SCI-Expanded)
2025
20255. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)
Majidova N., YASLIKAYA Ş., Mildanoglu M. M., COŞKUN A., ERCAN UZUNDAL D., ŞAHİN T. K., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
20256. Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross-Sectional Study
ŞAHİN T. K., Sahin E. A., Gungor H. N., GÜVEN D. C., BARIŞTA İ., AKIN S.
CANCER MEDICINE
, sa.7, 2025 (SCI-Expanded, Scopus)
2025
20257. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors
ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
, sa.4, ss.129-137, 2025 (SCI-Expanded)
2025
20258. Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitors
BAŞ O., Tokatli M., Savkliyildiz M., Yazarkan Y., Guduk N., Kilinc C., et al.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.4, ss.405-409, 2025 (SCI-Expanded)
2025
20259. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
Sahin T. K., Rizzo A., GÜVEN D. C., AKSOY S.
CANCER TREATMENT REVIEWS
, 2025 (SCI-Expanded, Scopus)
2025
202510. Clinical Characteristics and Management of Patients Admitted to the Supportive Care Clinic and Predisposing Factors of Unplanned Hospital Readmission: Single-Center Experience
BAŞ O., Tokatli M., Guduk N., Erdogan D., Boyraz N. E., Cengelci C., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.8, 2025 (SCI-Expanded, Scopus)
2025
202511. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.6, 2025 (SCI-Expanded, Scopus)
2025
202512. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study
Kalkan Z., Ebinç S., Arcagok M., BİLİCİ A., YILDIZ Ö., KILIÇKAP S., et al.
MEDICINA-LITHUANIA
, sa.4, 2025 (SCI-Expanded, Scopus)
2025
202513. Serum Albumin-Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer
BAŞ O., Guduk N., Tokatli M., Guven D. C., ÖZER N., ŞENER Y. Z., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.5, 2025 (SCI-Expanded, Scopus)
2025
202514. The perspectives and knowledge of patients with cancer on mpox and mpox vaccination: a cross-sectional study
ŞAHİN T. K., KAYGUSUZ Y., Icli M. C., AKSOY S., GÜVEN D. C.
CURRENT MEDICAL RESEARCH AND OPINION
, sa.1, ss.83-91, 2025 (SCI-Expanded, Scopus)
2025
202515. The association between HALP score and survival in patients treated with immune checkpoint inhibitors
ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.1, ss.81-89, 2025 (SCI-Expanded)
2024
202416. Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model
Comes M. C., Fanizzi A., Bove S., Boldrini L., Latorre A., GÜVEN D. C., et al.
CANCER MEDICINE
, cilt.13, sa.24, 2024 (SCI-Expanded, Scopus)
2024
202417. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
Kahraman S., Hizal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., et al.
BMC CANCER
, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
2024
202418. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer
YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.
BMC CANCER
, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
2024
202419. Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis
Vitale E., Rizzo A., Maistrello L., GÜVEN D. C., Massafra R., Mollica V., et al.
SCIENTIFIC REPORTS
, cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)
2024
202420. Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer
KAVGACI G., ŞAHİN T. K., Muderrisoglu T., Ileri S., GÜVEN D. C., AKSOY S.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.12, ss.1319-1326, 2024 (SCI-Expanded)
2024
202421. Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
AKYILDIZ A., Ismayilov R., Abdurrahimli N., Ormanci A., GÜVEN D. C., TUNCEL M., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
, sa.2, ss.100-105, 2024 (SCI-Expanded, Scopus)
2024
202422. Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis
Sahin T. K., Guven D. C.
CLINICAL NUTRITION ESPEN
, cilt.63, ss.829-836, 2024 (ESCI, Scopus)
2024
202423. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.
JOURNAL OF CHEMOTHERAPY
, 2024 (SCI-Expanded, Scopus)
2024
202424. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)
AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
, cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus)
2024
202425. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab
YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.
BIOMOLECULES AND BIOMEDICINE
, cilt.24, sa.4, ss.998-1003, 2024 (SCI-Expanded, Scopus)
2024
202426. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer
YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.
MEDICINE
, cilt.103, sa.30, 2024 (SCI-Expanded, Scopus)
2024
202427. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors
KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.
SUPPORTIVE CARE IN CANCER
, cilt.32, sa.7, 2024 (SCI-Expanded, Scopus)
2024
202428. Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.
PHARMACEUTICALS
, cilt.17, sa.7, 2024 (SCI-Expanded, Scopus)
2024
202429. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review
GÜVEN D. C., KAVGACI G., ERUL E., Syed M. P., Magge T., Saeed A., et al.
ONCOLOGIST
, cilt.29, 2024 (SCI-Expanded, Scopus)
2024
202430. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis
Sahin T. K., Rizzo A., AKSOY S., Guven D. C.
CANCERS
, cilt.16, sa.10, 2024 (SCI-Expanded, Scopus)
2024
202431. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer
Schipilliti F. M., Drittone D., Mazzuca F., La Forgia D., GÜVEN D. C., Rizzo A.
Heliyon
, cilt.10, sa.7, 2024 (SCI-Expanded, Scopus)
2024
202432. The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis
Guven D. C., Sahin T. K.
Breast Cancer Research and Treatment
, cilt.204, sa.3, ss.443-452, 2024 (SCI-Expanded, Scopus)
2024
202433. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.
International Journal of Clinical Oncology
, cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)
2024
202434. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer
Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., Ersoy M., et al.
Future oncology (London, England)
, cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded, Scopus)
2024
202435. Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review
GÜVEN D. C., Thong M. S., Arndt V.
Journal of Cancer Survivorship
, 2024 (SCI-Expanded, SSCI, Scopus)
2024
202436. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing
KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.
Journal of Chemotherapy
, 2024 (SCI-Expanded, Scopus)
2024
202437. Editorial: Advances in the treatment of hormonal receptor positive (HR plus ) breast cancer
Ben Kridis W., Wang Z., GÜVEN D. C., Dharmarajan A.
FRONTIERS IN ONCOLOGY
, cilt.14, 2024 (SCI-Expanded, Scopus)
2024
202438. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.
INTEGRATIVE CANCER THERAPIES
, cilt.23, 2024 (SCI-Expanded, Scopus)
2024
202439. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)
BİLGİN E., Demirci Yıldırım T., Özdemir Ulusoy B., Öğüt T. S., Karabacak M., Sadioğlu Çağdaş Ö., et al.
Internal and Emergency Medicine
, 2024 (SCI-Expanded, Scopus)
2024
202440. Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis
GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., AKSOY S.
Laryngoscope
, cilt.134, sa.1, ss.7-17, 2024 (SCI-Expanded, Scopus)
2024
202441. Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes
Rizzo A., Rinaldi L., Massafra R., Cusmai A., GÜVEN D. C., Forgia D. L., et al.
FUTURE ONCOLOGY
, cilt.20, sa.20, ss.1427-1434, 2024 (SCI-Expanded, Scopus)
2024
202442. Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy
Sahin T. K., ÖZBAY Y., ALTUNBULAK A. Y., ALTUNBULAK H. İ., ONUR M. R., Ceylan F., et al.
International Journal of Clinical Oncology
, 2024 (SCI-Expanded, Scopus)
2024
202443. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study
Karadurmus N., Kaplan M. A., Sendur M. A. N., ÜRÜN Y., Demirci U., Karaca S. B., et al.
CURRENT MEDICAL RESEARCH AND OPINION
, cilt.40, ss.1171-1178, 2024 (SCI-Expanded, Scopus)
2024
202444. Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors
Laface C., Fina E., Ricci A. D., GÜVEN D. C., Ambrogio F., De Summa S., et al.
EXPERT OPINION ON BIOLOGICAL THERAPY
, cilt.24, ss.1363-1374, 2024 (SCI-Expanded, Scopus)
2024
202445. Sirolimus experience in adult patients with vascular malformations
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.
Vascular
, 2024 (SCI-Expanded, Scopus)
2024
202446. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study
Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.
Cancer Medicine
, cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)
2023
202347. Comparison between vision transformers and convolutional neural networks to predict non-small lung cancer recurrence
Fanizzi A., Fadda F., Comes M. C., Bove S., Catino A., Di Benedetto E., et al.
Scientific Reports
, cilt.13, sa.1, 2023 (SCI-Expanded, Scopus)
2023
202348. A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology
YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.
Irish Journal of Medical Science
, cilt.192, sa.6, ss.2631-2634, 2023 (SCI-Expanded, Scopus)
2023
202349. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., et al.
Medicine
, cilt.102, sa.45, 2023 (SCI-Expanded, Scopus)
2023
202350. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer
YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., et al.
Anti-cancer drugs
, cilt.34, sa.10, ss.1190-1192, 2023 (SCI-Expanded, Scopus)
2023
202351. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.
Journal of Immunotherapy and Precision Oncology
, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
2023
202352. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.
Current Oncology
, cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)
2023
202353. Looking at FOxTROT Through the Lens of IDEA
GÜVEN D. C.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
, cilt.41, sa.30, ss.4821-4822, 2023 (SCI-Expanded, Scopus)
2023
202354. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data
EROL C., HAFIZOĞLU E., aykan m. b., GÜVEN D. C., Dursun B., Hizal M., et al.
ACTA ONCOLOGICA TURCICA
, cilt.56, sa.2, ss.170-179, 2023 (TRDizin)
2023
202355. Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer
Şener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., et al.
Strahlentherapie und Onkologie
, cilt.199, sa.8, ss.761-772, 2023 (SCI-Expanded, Scopus)
2023
202356. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives
ERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.
European Archives of Oto-Rhino-Laryngology
, cilt.280, sa.8, ss.3541-3556, 2023 (SCI-Expanded, Scopus)
2023
202357. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.
Anti-Cancer Drugs
, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)
2023
202358. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)
2023
202359. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.8, ss.4141-4148, 2023 (SCI-Expanded, Scopus)
2023
202360. SMART syndrome: a case report
Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.
ACTA NEUROLOGICA BELGICA
, cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded, Scopus)
2023
202361. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.
Medicine (United States)
, cilt.102, sa.18, 2023 (SCI-Expanded, Scopus)
2023
202362. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma
GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.
European Archives of Oto-Rhino-Laryngology
, cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded, Scopus)
2023
202363. Learning From Failure: Negative Trials in Oncology
Nardo M., GÜVEN D. C., Yikilmaz A. S., Singh S., Ahmed J.
Journal of Immunotherapy and Precision Oncology
, cilt.6, sa.2, ss.59-60, 2023 (Scopus)
2023
202364. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.
Future oncology (London, England)
, cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded, Scopus)
2023
202365. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer
Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.
Clinics and Research in Hepatology and Gastroenterology
, cilt.47, sa.3, 2023 (SCI-Expanded, Scopus)
2023
202366. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
Akagunduz B., Guven D. C., Ozer M., Okten I. N., Atag E., Unek İ. T., et al.
Journal of Geriatric Oncology
, cilt.14, sa.2, 2023 (SCI-Expanded, Scopus)
2023
202367. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.
INTERNATIONAL JOURNAL OF CANCER
, cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)
2023
202368. Emerging treatment strategies in hepatobiliary cancer
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus)
2023
202369. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience
Erol C., Bardakçi M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., et al.
Journal of Oncological Science
, cilt.9, sa.2, ss.72-78, 2023 (Scopus, TRDizin)
2023
202370. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.
Journal of Oncological Science
, cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin)
2023
202371. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)
2022
202272. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., et al.
Frontiers in Molecular Biosciences
, cilt.9, 2022 (SCI-Expanded, Scopus)
2022
202273. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
Gurbuz M., Kutlu Y., AKKUŞ E., KÖKSOY E. B., Kose N., Oven B. B., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded, Scopus)
2022
202274. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review
YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
, cilt.15, sa.4, ss.307-310, 2022 (ESCI, Scopus)
2022
202275. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.
BREAST
, cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)
2022
202276. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards
GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded, Scopus)
2022
202277. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.
ONCOLOGIST
, cilt.27, sa.11, 2022 (SCI-Expanded, Scopus)
2022
202278. Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis
BAŞ O., Erul E., GÜVEN D. C., AKSOY S.
SUPPORTIVE CARE IN CANCER
, cilt.30, sa.11, ss.9071-9078, 2022 (SCI-Expanded, Scopus)
2022
202279. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
Carloni R., Rizzo A., Ricci A. D., Di Federico A., De Luca R., GÜVEN D. C., et al.
TRANSLATIONAL ONCOLOGY
, cilt.25, 2022 (SCI-Expanded, Scopus)
2022
202280. The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
GÜVEN D. C., ŞAHİN T. K., Rizzo A., Ricci A. D., AKSOY S., ŞAHİN K.
APPLIED SCIENCES-BASEL
, cilt.12, sa.20, 2022 (SCI-Expanded, Scopus)
2022
202281. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)
2022
202282. Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
Rizzo A., Carloni R., Ricci A. D., Di Federico A., GÜVEN D. C., YALÇIN Ş., et al.
JOURNAL OF PERSONALIZED MEDICINE
, cilt.12, sa.8, 2022 (SCI-Expanded, Scopus)
2022
202283. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)
2022
202284. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report
TABAN H., GÜVEN D. C., Kilickap S.
CUREUS JOURNAL OF MEDICAL SCIENCE
, cilt.14, sa.8, 2022 (ESCI)
2022
202285. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded, Scopus)
2022
202286. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus)
2022
202287. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis
GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.
CANCERS
, cilt.14, sa.11, 2022 (SCI-Expanded, Scopus)
2022
202288. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.
Guven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)
2022
202289. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group
Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., et al.
JOURNAL OF GASTROINTESTINAL CANCER
, cilt.53, sa.2, ss.282-288, 2022 (ESCI, Scopus)
2022
202290. The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials
GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., Erul E., AKSOY S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
, cilt.174, 2022 (SCI-Expanded, Scopus)
2022
202291. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination
GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.
ONCOLOGIST
, cilt.27, 2022 (SCI-Expanded, Scopus)
2022
202292. HER2-low breast cancer could be associated with an increased risk of brain metastasis
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus)
2022
202293. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.
Journal of Oncological Science
, cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)
2022
202294. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)
2022
202295. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.52, sa.5, ss.1559-1568, 2022 (SCI-Expanded, Scopus, TRDizin)
2022
202296. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment
GÜRLER F., Ilhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., et al.
ANTI-CANCER DRUGS
, cilt.33, sa.1, 2022 (SCI-Expanded, Scopus)
2022
202297. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.
FUTURE ONCOLOGY
, cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus)
2022
202298. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin)
2021
202199. Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats
AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.32, sa.12, ss.1049-1056, 2021 (SCI-Expanded, Scopus, TRDizin)
2021
2021100. Assessment of abuse and related factors in older patients with cancer
Akagunduz B., Altin Z., Atci M. M., Ozer M., GÜVEN D. C., Cil I., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.12, ss.7957-7964, 2021 (SCI-Expanded, Scopus)
2021
2021101. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study
GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.
CURRENT PROBLEMS IN CANCER
, cilt.45, sa.6, 2021 (SCI-Expanded, Scopus)
2021
2021102. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
, cilt.168, 2021 (SCI-Expanded, Scopus)
2021
2021103. Thirty-day mortality rates after immunotherapy initiation
SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., et al.
IMMUNOTHERAPY
, cilt.13, ss.1419-1426, 2021 (SCI-Expanded, Scopus)
2021
2021104. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M.
FRONTIERS IN ONCOLOGY
, cilt.11, 2021 (SCI-Expanded, Scopus)
2021
2021105. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy
AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
, cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)
2021
2021106. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme
GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.
FUTURE ONCOLOGY
, cilt.17, ss.4405-4413, 2021 (SCI-Expanded, Scopus)
2021
2021107. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
2021108. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
2021
2021109. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors
GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.
BIOMARKERS IN MEDICINE
, cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus)
2021
2021110. Sarcopenia and anthracycline cardiotoxicity in patients with cancer
BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
2021111. Neoadjuvant capecitabine in rectal cancer chemoradiotherapy: too early to ring the alarms
GÜVEN D. C., YALÇIN Ş.
INTERNAL MEDICINE JOURNAL
, cilt.51, sa.8, ss.1365-1366, 2021 (SCI-Expanded, Scopus)
2021
2021112. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report
GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.27, sa.5, ss.1281-1283, 2021 (SCI-Expanded, Scopus)
2021
2021113. Reassurance of patients with cancer on cancer care continuum: a vital strategy to prevent anxiety of COVID-19 collateral damage
GÜVEN D. C.
SUPPORTIVE CARE IN CANCER
, cilt.29, ss.3423-3424, 2021 (SCI-Expanded, Scopus)
2021
2021114. Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review
Yigit E., GÜVEN D. C., AKSOY S., YAZICI G.
CUREUS
, cilt.13, sa.6, 2021 (ESCI)
2021
2021115. A novel agnostic tumor: NTRKoma
Ayasun R., GÜVEN D. C., Gullu İ. H.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.27, sa.4, ss.802-803, 2021 (SCI-Expanded, Scopus)
2021
2021116. Artificial intelligence method to predict overall survival of hepatocellular carcinoma
ŞİMŞEK C., GÜVEN D. C., Sahin T. K., TEKİN İ. E., Sahan O., BALABAN H. Y., et al.
Hepatology Forum
, cilt.2, sa.2, ss.64-68, 2021 (Scopus)
2021
2021117. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION
, cilt.36, 2021 (SCI-Expanded, Scopus)
2021
2021118. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer
Turker S., Cilbir E., GÜVEN D. C., Karacin C., YALÇIN Ş.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
, cilt.17, sa.2, ss.510-515, 2021 (SCI-Expanded, Scopus)
2021
2021119. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus)
2021
2021120. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma
AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.
TURKISH JOURNAL OF UROLOGY
, cilt.47, sa.2, ss.113-119, 2021 (ESCI, Scopus, TRDizin)
2021
2021121. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.
CANCER RESEARCH
, cilt.81, sa.4, 2021 (SCI-Expanded, Scopus)
2021
2021122. Thyroid gland metastasis mimicking thyroid carcinoma in a lung cancer patient and dramatic response to crizotinib: A case report
Erul E., GÜVEN D. C., ŞAHİN T. K., Gullu İ. H.
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX
, cilt.69, sa.1, ss.98-101, 2021 (ESCI, Scopus, TRDizin)
2020
2020123. The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters
GÜVEN D. C., ŞAHİN T. K., AKSOY S.
BREAST JOURNAL
, cilt.26, sa.12, ss.2435-2436, 2020 (SCI-Expanded, Scopus)
2020
2020124. Cancer incidence in Behcet's disease
GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEN B., AKTAŞ B. Y., KİRAZ S., et al.
IRISH JOURNAL OF MEDICAL SCIENCE
, cilt.189, sa.4, ss.1209-1214, 2020 (SCI-Expanded, Scopus)
2020
2020125. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)
Alkan A., Yasar A., Guc Z. G., Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., et al.
EUROPEAN JOURNAL OF CANCER CARE
, cilt.29, sa.6, 2020 (SCI-Expanded, SSCI, Scopus)
2020
2020126. Effects of adenosine triphosphate on vandetanib induced skin damage in rats
Akagunduz B., ÖZÇİÇEK F., Kara A. V., GÜVEN D. C., YAZICI G. N., Coban A., et al.
CUTANEOUS AND OCULAR TOXICOLOGY
, cilt.39, sa.4, ss.323-327, 2020 (SCI-Expanded, Scopus)
2020
2020127. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design
GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.
CLINICAL COLORECTAL CANCER
, cilt.19, sa.3, 2020 (SCI-Expanded, Scopus)
2020
2020128. All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past
Ceylan F., GÜVEN D. C., ŞAHİN T. K., ÖZBEK D. A., DİZDAR Ö.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.43, sa.9, ss.676, 2020 (SCI-Expanded, Scopus)
2020
2020129. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19
GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.
FRONTIERS IN ONCOLOGY
, cilt.10, 2020 (SCI-Expanded, Scopus)
2020
2020130. Cancer incidence in Behcet's Disease.
Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)
2020
2020131. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications
GÜVEN D. C., AKTAŞ B. Y., ŞİMŞEK C., AKSOY S.
FUTURE ONCOLOGY
, cilt.16, sa.9, ss.497-506, 2020 (SCI-Expanded, Scopus)
2020
2020132. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient
KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.2, ss.496-499, 2020 (SCI-Expanded, Scopus)
2020
2020133. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer
GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.1, ss.256-258, 2020 (SCI-Expanded, Scopus)
2019
2019134. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study
Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., et al.
JOURNAL OF BUON
, cilt.24, sa.6, ss.2327-2332, 2019 (SCI-Expanded, Scopus)
2019
2019135. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy
AKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.
EXPERT REVIEW OF ANTICANCER THERAPY
, cilt.19, sa.7, ss.589-601, 2019 (SCI-Expanded, Scopus)
2019
2019136. Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients
Guven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.
BIOMARKERS IN MEDICINE
, cilt.13, sa.9, ss.725-735, 2019 (SCI-Expanded, Scopus)
2019
2019137. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia
BİLGİN E., DİZDAR Ö., Guven D. C., Ceylan S., AYBI Ö., FIRLATAN B., et al.
Rheumatology International
, cilt.39, sa.6, ss.1045-1051, 2019 (SCI-Expanded, Scopus)
2019
2019138. Evaluation of cancer risk in patients with periodontal diseases
Guven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.49, sa.3, ss.826-831, 2019 (SCI-Expanded, Scopus, TRDizin)
2018
2018139. A rare cause of proximal muscle weakness: immune necrotising myopathy
GÜVEN D. C., ERDEN A., KILIÇ L., ERDEM ÖZDAMAR S., KARADAĞ Ö.
SCOTTISH MEDICAL JOURNAL
, cilt.63, sa.3, ss.82-86, 2018 (SCI-Expanded, Scopus)
2018
2018140. Fusobacterium and colorectal carcinogenesis
Guven D. C., DİZDAR Ö.
CARCINOGENESIS
, cilt.39, sa.1, ss.84, 2018 (SCI-Expanded, Scopus)
2017
2017141. Increased cancer risk in patients with periodontitis
DİZDAR Ö., HAYRAN M., Guven D. C., YILMAZ T. B., TAHERI S., AKMAN A. C., et al.
CURRENT MEDICAL RESEARCH AND OPINION
, cilt.33, sa.12, ss.2195-2200, 2017 (SCI-Expanded, Scopus)
2016
2016142. An Unusual Case of Tuberculosis Lenfadenitis Mimicking Tularemia
Başpınar B., HELVACI Ö., GÜVEN D. C., İNKAYA A. Ç.
Turkiye Klinikleri Journal of Internal Medicine
, cilt.1, sa.2, ss.111-113, 2016 (Hakemli Dergi)
2016
2016143. Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment
ATEŞ Ö., GÜVEN D. C., BABACAN T., Sunar V., Sarici F., AKSOY S., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.4, ss.206-214, 2016 (SCI-Expanded, Scopus, TRDizin)
2015
2015144. Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life Results
KALYONCU U., Erden A., KILIÇ L., Seyhoglu E., Guven D. C., AKTAŞ B. Y., et al.
ARTHRITIS & RHEUMATOLOGY
, cilt.67, 2015 (SCI-Expanded, Scopus)
2014
2014145. Acute erythroid leukemia in a patient with chronic lymphocytic leukemia
GÜVEN D. C., BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.
JOURNAL OF BUON
, cilt.19, sa.4, ss.1127, 2014 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2019
20192. outcomes of patients with resected pancreatic ductal adenocarcinoma
ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.
9th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri)
2019
20193. MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?
BİLGİN E., GÜVEN D. C., Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C., FIRLATAN B., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.993, (Özet Bildiri)
2019
20194. Clinical features and prognosis of patients with liposarcoma: Single-center experience.
Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)
2018
20185. Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi
GÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., et al.
2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, (Tam Metin Bildiri)
2018
20186. Metastatic Choroidal Melanoma: Single Center Experience
AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al.
2. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, ss.1-48, (Tam Metin Bildiri)
2018
20187. Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorektal patients and healty controls. Abst ID:”e15117”
GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., et al.
2018 ASCO, Chicago, Amerika Birleşik Devletleri, 1 - 05 Haziran 2018, (Özet Bildiri)
2018
20188. Evaluation of cancer risk in patients with periodontal diseases.
GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., et al.
2018 ASCO Annual Meeting, Chicago, Amerika Birleşik Devletleri, 1 - 05 Haziran 2018, cilt.36, ss.13571, (Özet Bildiri)
2018
20189. Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi
GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2018, (Özet Bildiri)
2017
201710. SEVERE PERIODONTITIS IS ASSOCIATED WITH INCREASED CANCER RISK
DİZDAR Ö., HAYRAN K. M., GÜVEN D. C., Yılmaz T. B., Taheri S., AKMAN A. C., et al.
GAP 2017 Conference, Texas, Amerika Birleşik Devletleri, 9 - 11 Mayıs 2017, (Özet Bildiri)
Kitaplar
2017
20171. PATOFİZYOLOJİNİN TEMELLERİ
DURUSU TANRIÖVER M., SARI A., EŞME M., KOÇ YILDIRIM S., YILDIRIM M. Ş., BÖLEK E. Ç., et al.
PALME YAYINCILIK, 2017